RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts.
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Mol Cancer Ther. 2018 Jun;17(6):1251-1258. doi: 10.1158/1535-7163.MCT-17-1144. Epub 2018 Apr 13.
Glioblastoma (GBM) is the most common and lethal form of primary brain tumor with dismal median and 2-year survivals of 14.5 months and 18%, respectively. The paucity of new therapeutic agents stems from the complex biology of a highly adaptable tumor that uses multiple survival and proliferation mechanisms to circumvent current treatment approaches. Here, we investigated the potency of a new generation of siRNAs to silence gene expression in orthotopic brain tumors generated by transplantation of human glioma stem-like cells in athymic nude mice. We demonstrate that cholesterol-conjugated, nuclease-resistant siRNAs (Chol-hsiRNAs) decrease mRNA and silence luciferase expression by 90% in GBM neurospheres. Furthermore, Chol-hsiRNAs distribute broadly in brain tumors after a single intratumoral injection, achieving sustained and potent (>45% mRNA and >90% protein) tumor-specific gene silencing. This readily available platform is sequence-independent and can be adapted to target one or more candidate GBM driver genes, providing a straightforward means of modulating GBM biology .
胶质母细胞瘤(GBM)是最常见和致命的原发性脑肿瘤,其中位生存期和 2 年生存率分别为 14.5 个月和 18%。缺乏新的治疗药物的原因在于肿瘤具有复杂的生物学特性,它使用多种生存和增殖机制来规避当前的治疗方法。在这里,我们研究了新一代 siRNA 沉默荷瘤鼠原位脑肿瘤中移植的人神经胶质瘤干细胞的基因表达的能力。我们证明胆固醇修饰的、核酸酶抗性 siRNA(Chol-hsiRNAs)可使 GBM 神经球中的 mRNA 减少 90%,并使荧光素酶表达沉默 90%。此外,Chol-hsiRNAs 在单次瘤内注射后广泛分布于脑肿瘤中,实现了持续和强效(>45%的 mRNA 和>90%的蛋白)的肿瘤特异性基因沉默。这种易于获得的平台是序列非依赖性的,可以针对一个或多个候选 GBM 驱动基因进行调整,为调节 GBM 生物学提供了一种简单的方法。